Climate Change Data

Medigen Vaccine Biologics Corp.

Climate Impact & Sustainability Data (2023)

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:5360.04 tCO2e/year (Scope 1: 1538.46 tons in 2023; Scope 2: 3821.58 tons in 2023)
Scope 1 Emissions:1538.46 tCO2e/year
Scope 2 Emissions:3821.58 tCO2e/year
Water Consumption:43.61 Million liters/year
Waste Generated:11.05 tons/year

ESG Focus Areas

  • Environmental Protection
  • Employee Well-being
  • Corporate Governance

Environmental Achievements

  • Reduced water consumption from 62.93 Million liters in 2022 to 43.61 Million liters in 2023
  • Reduced total waste from 10.01 tons in 2022 to 11.05 tons in 2023 (Note: slight increase, needs further investigation)

Social Achievements

  • Implemented various employee welfare measures including year-end bonuses, bonuses, employee education training, and group insurance.
  • Maintained a harmonious labor-management relationship with no labor disputes.

Governance Achievements

  • Established a chief governance officer to handle corporate governance matters.
  • Implemented a robust internal control system, regularly audited for compliance.

Climate Goals & Targets

Long-term Goals:
  • Conduct a greenhouse gas inventory and verify it by a third party; reduce carbon emissions by 1%-2% year by year; continue improving the equipment operation process and enhancing energy efficiency.
Medium-term Goals:
  • Conduct greenhouse gas inventory; reduce carbon emissions year by year; continuously improve equipment operation processes.
Short-term Goals:
  • Collect and survey internal carbon emission data; propose plans to improve equipment operation processes and enhance energy efficiency.

Environmental Challenges

  • Decreasing birth rate in Taiwan affecting the size of consumer groups for infant vaccines.
  • Relatively smaller scale of Taiwanese biotech companies compared to international pharmaceutical companies.
Mitigation Strategies
  • Pursuing a higher-price product strategy for differentiation and expanding into the ASEAN market.
  • Strengthening competitive advantage through international collaborations (WHO Solidarity Trial Vaccine, CEPI, WHO C-TAP).

Supply Chain Management

Responsible Procurement
  • Evaluates suppliers’ legality and ethical records; requires compliance with GMP, GDP, or other industry standards.

Climate-Related Risks & Opportunities

Physical Risks
  • Abnormal weather conditions, natural disasters (typhoons, floods, droughts)
Transition Risks
  • Carbon reduction policies and regulations
  • Control of corporate carbon footprint
  • Suppliers' compliance with relevant policies and regulations

Reporting Standards

Frameworks Used: GRI

Certifications: PIC/S GMP

Sustainable Products & Innovation

  • EV71 vaccine
  • Quadrivalent influenza vaccine
  • COVID-19 vaccine